Photo Source: Bureau for Cancer Research
OM-RCA-01 is a monoclonal antibody-based drug that selectively blocks the FGFR1 receptor. This protein is involved in the growth and spread of malignant tumors. According to the developer, the Bureau for Cancer Research, no analogues with this mechanism of action have been registered worldwide yet.
The clinical trial includes patients with metastatic lung, breast, kidney, and prostate cancer, as well as head and neck tumors. The study is being conducted at clinical centers in Moscow, St. Petersburg, Kazan, Ufa, Krasnoyarsk, and Ivanovo.
The development has already been recognized by the international professional community, the project received the ASCO Merit Award from the American Society of Clinical Oncology and an award from the European Association of Urology. Patents for the drug and its mechanism of action are registered in Russia, Europe, and the USA.
"OM-RCA-01 is a completely Russian development: from concept to finished product. We conducted preclinical efficacy and safety studies in independent laboratories in Russia, the USA, and Germany. Recent tests demonstrate 97% antibody-antigen binding, confirming its high biological activity," said Ilya Timofeev, Director of the Bureau for Cancer Research.
To participate in the study, patients must undergo preliminary consultation and assessment of eligibility criteria. "Before prescribing therapy, we confirm the presence of the FGFR1 target on tumor cells. This personalized approach significantly increases the chances of treatment effectiveness," noted Igor Utyashev, Principal Investigator and Director of the Clinical Research Department at Hadassah Clinic in Skolkovo.
Source: Interfax
All information on this website is provided for informational purposes only and does not constitute medical advice. All medical procedures require prior consultation with a licensed physician. Treatment outcomes may vary depending on individual characteristics. We do not guarantee any specific results. Always consult a medical professional before making any healthcare decisions.